CODAC Behavioral Healthcare President and CEO, Linda Hurley, has been awarded the 2022 Lifetime Achievement Award by The Rhode Island Public Health Association for her efforts in developing and …
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
|
CODAC Behavioral Healthcare President and CEO, Linda Hurley, has been awarded the 2022 Lifetime Achievement Award by The Rhode Island Public Health Association for her efforts in developing and promoting comprehensive, accessible, non-stigmatizing addiction care for all. The award was presented at 25th Annual Meeting of The Rhode Island Public Health Association on November 15 at Rhodes on the Pawtuxet in Cranston. The award is presented to an individual who has made significant contributions to advance the public’s health at a national, state, or local level. Selection criteria is based upon recognition by a group of professionals, public health peers long familiar with the development and advancement of public health in Rhode Island. Linda was recognized for pioneering and leading efforts at the organization, state, and national levels to develop and promote comprehensive, accessible, non-stigmatizing addiction care for all. Linda has worked in substance abuse treatment and behavioral healthcare for more than 30 years. She has been with CODAC since 1991 and was named CODAC’s President/CEO in 2016. Under her leadership, CODAC was the first Opioid Treatment Program (OTP) in the nation to receive Health Home certification and the first OTP in RI to be designated as a Center of Excellence. She established a first of its kind comprehensive Medication Assisted Treatment (MAT) Program for corrections in the nation, a recognized Tobacco Cessation program, one of the first HCV treatment programs embedded in an OTP and launched a first in the nation medical mobile unit approved to dispense all three FDA-approved medications for the treatment of OUD.